Edgestream Partners’s BridgeBio Pharma BBIO Stock Holding History

Edgestream Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-54,844	Closed	-$4.2M	–	886
2025 Q4	$4.2M	Sell	54,844 -45,942	-46%	-$3.02M	0.12%	308
2025 Q3	$5.23M	Buy	100,786 +56,230	+126%	+$2.74M	0.15%	232
2025 Q2	$1.92M	Buy	+44,556	New	+$1.62M	0.05%	534
2025 Q1	–	Sell	-56,235	Closed	-$1.54M	–	843
2024 Q4	$1.54M	Buy	+56,235	New	+$1.45M	0.07%	456
2024 Q2	–	Sell	-43,115	Closed	-$1.33M	–	848
2024 Q1	$1.33M	Sell	43,115 -7,187	-14%	-$244K	0.07%	438
2023 Q4	$2.03M	Buy	50,302 +35,262	+234%	+$1.06M	0.15%	234
2023 Q3	$397K	Buy	15,040 +598	+4%	+$17K	0.03%	644
2023 Q2	$248K	Buy	+14,442	New	+$217K	0.02%	657

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Edgestream Partners's BBIO Position: Q1 2026 in Review

Edgestream Partners sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 54,844 shares — an estimated $4.2M sold.

Edgestream Partners first reported a position in BBIO in Q2 2023 and held it in 8 quarters. The position peaked at $5.23M in Q3 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Edgestream Partners reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Edgestream Partners sold 54,844 BridgeBio Pharma shares in Q1 2026, an estimated $4.2M.
Edgestream Partners first reported a position in BridgeBio Pharma in Q2 2023 and held it in 8 quarters.
Edgestream Partners's BridgeBio Pharma position peaked at $5.23M in Q3 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.